跳到主要內容

Trizzino John 的 Form 4 申報

Novavax Inc(NVAX),2021/9/29 申報

申報編號
0001209191-21-058075
申報時間
2021/9/29
交易日
2021/9/28
申報延遲
1 天
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 19 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $157.5 萬。交易後 1 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Trizzino JohnCIK 0001468534高階主管(EVP, CCO and CBO)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2021/9/28Common StockM行使選擇權取得+7,501$19.08+$143,119.0810,047直接
2021/9/28Common StockS賣出處分−839$203.26F2−$170,535.149,208直接
2021/9/28Common StockS賣出處分−1,141$204.12F3−$232,900.928,067直接
2021/9/28Common StockS賣出處分−1,452$205.25F4−$298,0236,615直接
2021/9/28Common StockS賣出處分−990$206.30F5−$204,2375,625直接
2021/9/28Common StockS賣出處分−382$207.32F6−$79,196.245,243直接
2021/9/28Common StockS賣出處分−312$208.46F7−$65,039.524,931直接
2021/9/28Common StockS賣出處分−112$209.57F8−$23,471.844,819直接
2021/9/28Common StockS賣出處分−100$211.45−$21,1454,719直接
2021/9/28Common StockS賣出處分−30$213.11−$6,393.34,689直接
2021/9/28Common StockS賣出處分−318$214.65F9−$68,258.74,371直接
2021/9/28Common StockS賣出處分−247$216.21F10−$53,403.874,124直接
2021/9/28Common StockS賣出處分−226$218.13F11−$49,297.383,898直接
2021/9/28Common StockS賣出處分−421$219.26F12−$92,308.463,477直接
2021/9/28Common StockS賣出處分−49$220.22F13−$10,790.783,428直接
2021/9/28Common StockS賣出處分−255$222.86F14−$56,829.33,173直接
2021/9/28Common StockS賣出處分−148$224.24F15−$33,187.523,025直接
2021/9/28Common StockS賣出處分−323$228.25F16−$73,724.752,702直接
2021/9/28Common StockS賣出處分−156$230.00F17−$35,8802,546直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2021/9/28Common StockM行使選擇權處分−7,501$0.00$095,000直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F2

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.69 to $203.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F3

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.73 to $204.71, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F4

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.83 to $205.80, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F5

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.84 to $206.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F6

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.94 to $207.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F7

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.14 to $208.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F8

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.29 to $209.85, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F9

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.41 to $215.01, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F10

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.85 to $216.51, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F11

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.87 to $218.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F12

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.95 to $219.50, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F13

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.21 to $220.23, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F14

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.20 to $222.98, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F15

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.02 to $224.80, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F16

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.19 to $228.42, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F17

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.94 to $230.03, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)